Summary
Controls Blood Gases Non-invasively to Stimulate Vascular Reactivity.
Cited in 150+ Articles Published in Peer Reviewed Journals
Used by 50+ elite research institutions globally contributing to 2/3 of all RespirAct® RA-MR™ cited publications.
RespirAct® RA-MR™ System Overview
Previous
Next
Select Research Institutions
University Health Network |
University of Toronto |
The Hospital for Sick Children |
Duke University |
Univeristy of Zurich |
Purdue University |
Samsung Medical Centre |
Medical College of Wisconsin |
University of Manitoba |
University of Delaware |
Concordia University |
University of Texas Health Science Center at Houston |
University of Exeter |
Mayo Clinic |
Cedars-Sinai Medical Center |
Children’s Hospital Los Angeles |
Max Planck Society |
University of British Columbia |
Louisiana State University |
University Medical Center Utrecht |
Queen’s University |
St. Joseph’s Health Care London |
University of Calgary |
Northwestern University |
Erasmus University Rotterdam |
The University of Texas at Dallas |
University of Pennsylvania |
Johns Hopkins University |
British Columbia Children’s Hospital |
Cardiff University |
St. Michael’s Hospital |
Wake Forest University |
Western University |
Robarts Research Institute |
Pfizer |
Ottawa Heart Institute |
Washington University, St. Louis |
University of California Davis |
University of Wisconsin |
Important Note
The RespirAct® RA-MR™ has not been evaluated by the FDA and is distributed by Thornhill Medical to collaborators for use in IRB approved basic physiological research studies. The RespirAct® RA-MR™ system is not intended to be used in the diagnosis or treatment of disease and is not intended to be used in studies that evaluate its safety or efficacy. More details can be found on the RespirAct® RA-MR™ Forum.